{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T01:10:02Z","timestamp":1750209002842,"version":"3.41.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T00:00:00Z","timestamp":1742774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology Reports"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.toxrep.2025.102010","type":"journal-article","created":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T05:02:58Z","timestamp":1742965378000},"page":"102010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Fixed drug eruption induced by Etoricoxib in Thailand: A case report"],"prefix":"10.1016","volume":"14","author":[{"given":"Metar","family":"Siriwattanasatorn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atiwut","family":"Kamudhamas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nakarin","family":"Sivapornpan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathavadee","family":"Noonpugdee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuntida","family":"Kamalashiran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8906-9968","authenticated-orcid":false,"given":"Pratya","family":"Phetkate","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.toxrep.2025.102010_bib1","article-title":"Prospective analysis of cutaneous adverse drug reactions encountered in a tertiary care hospital","volume":"16","author":"Dhage","year":"2024","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.toxrep.2025.102010_bib2","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00128071-200001050-00003","article-title":"Fixed drug eruptions. Incidence, recognition, and avoidance","volume":"1","author":"Lee","year":"2000","journal-title":"Am. J. Clin. Dermatol."},{"issue":"2","key":"10.1016\/j.toxrep.2025.102010_bib3","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1600-0536.2010.01847.x","article-title":"Fixed drug eruption caused by etoricoxib--2 cases confirmed by patch testing","volume":"64","author":"Andrade","year":"2011","journal-title":"Contact Dermat."},{"key":"10.1016\/j.toxrep.2025.102010_bib4","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.toxrep.2018.10.006","article-title":"Cefotaxime induced generalized bullous fixed drug eruption - a case report","volume":"5","author":"Manikandan","year":"2018","journal-title":"Toxicol. Rep."},{"issue":"9","key":"10.1016\/j.toxrep.2025.102010_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/medicina57090925","article-title":"A Review of Fixed Drug Eruption with a Special Focus on Generalized Bullous Fixed Drug Eruption","volume":"57","author":"Anderson","year":"2021","journal-title":"Medicina"},{"issue":"11","key":"10.1016\/j.toxrep.2025.102010_bib6","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1046\/j.1365-4362.1998.00451.x","article-title":"Drugs causing fixed eruptions: a study of 450 cases","volume":"37","author":"Mahboob","year":"1998","journal-title":"Int J. Dermatol."},{"issue":"8","key":"10.1016\/j.toxrep.2025.102010_bib7","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/j.1365-4632.2006.02853.x","article-title":"Fixed drug eruption (FDE): changing scenario of incriminating drugs","volume":"45","author":"Sehgal","year":"2006","journal-title":"Int J. Dermatol."},{"key":"10.1016\/j.toxrep.2025.102010_bib8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.toxrep.2024.02.006","article-title":"NSAID (nonsteroidal anti-inflammatory drugs) Induced Stevens Johnson Syndrome in a 50-year-old woman: a case study","volume":"12","author":"Faraji","year":"2024","journal-title":"Toxicol. Rep."},{"issue":"3","key":"10.1016\/j.toxrep.2025.102010_bib9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/cod.13659","article-title":"Gamboa Seti\u00e9n PM. Etoricoxib-induced fixed drug eruption: report of seven cases","volume":"84","author":"Mart\u00ednez Ant\u00f3n","year":"2021","journal-title":"Contact Dermat."},{"issue":"6","key":"10.1016\/j.toxrep.2025.102010_bib10","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.bjoms.2024.05.001","article-title":"Fixed drug eruption secondary to etoricoxib","volume":"62","author":"Rawlings","year":"2024","journal-title":"Br. J. Oral. Maxillofac. Surg."},{"issue":"4","key":"10.1016\/j.toxrep.2025.102010_bib11","doi-asserted-by":"crossref","first-page":"307","DOI":"10.18176\/jiaci.0384","article-title":"The lymphocyte transformation test is useful in the diagnosis of fixed drug eruption induced by etoricoxib","volume":"29","author":"Movsisyan","year":"2019","journal-title":"J. Invest. Allergol. Clin. Immunol."},{"issue":"4","key":"10.1016\/j.toxrep.2025.102010_bib12","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/ACI.0b013e32832cda4c","article-title":"Fixed drug eruption: pathogenesis and diagnostic tests","volume":"9","author":"Shiohara","year":"2009","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.toxrep.2025.102010_bib13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1610-0387.2007.06491.x","article-title":"Fixed drug eruption: state of the art","volume":"6","author":"Ozkaya","year":"2008","journal-title":"J. Dtsch Dermatol. Ges."},{"issue":"6","key":"10.1016\/j.toxrep.2025.102010_bib14","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1586\/eci.11.66","article-title":"The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"7","author":"Mockenhaupt","year":"2011","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"3","key":"10.1016\/j.toxrep.2025.102010_bib15","first-page":"201","article-title":"Fixed drug eruption: a disease mediated by self-inflicted responses of intraepidermal T cells","volume":"17","author":"Shiohara","year":"2007","journal-title":"Eur. J. Dermatol."},{"issue":"4","key":"10.1016\/j.toxrep.2025.102010_bib16","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0002-9440(10)64410-0","article-title":"Direct evidence for interferon-gamma production by effector-memory-type intraepidermal T cells residing at an effector site of immunopathology in fixed drug eruption","volume":"161","author":"Mizukawa","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.toxrep.2025.102010_bib17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1159\/000335623","article-title":"Fixed drug eruption: the dark side of activation of intraepidermal CD8+ T cells uniquely specialized to mediate protective immunity","volume":"97","author":"Shiohara","year":"2012","journal-title":"Chem. Immunol. Allergy"},{"issue":"5","key":"10.1016\/j.toxrep.2025.102010_bib18","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1590\/abd1806-4841.20164301","article-title":"Fixed drug eruption by etoricoxib confirmed by patch test","volume":"91","author":"Sousa","year":"2016","journal-title":"Bras. Dermatol."},{"issue":"2","key":"10.1016\/j.toxrep.2025.102010_bib19","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1081-1206(10)61205-7","article-title":"Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug\u2013induced urticaria and angioedema","volume":"95","author":"S\u00e1nchez-Borges","year":"2005","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"4","key":"10.1016\/j.toxrep.2025.102010_bib20","doi-asserted-by":"crossref","first-page":"307","DOI":"10.4103\/0378-6323.26732","article-title":"Fixed drug eruption and generalised erythema following etoricoxib","volume":"72","author":"Augustine","year":"2006","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"issue":"4","key":"10.1016\/j.toxrep.2025.102010_bib21","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4103\/ijd.IJD_481_17","article-title":"Fixed-drug eruptions: what can we learn from a case series?","volume":"63","author":"Jhaj","year":"2018","journal-title":"Indian J. Dermatol."},{"issue":"6","key":"10.1016\/j.toxrep.2025.102010_bib22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1034\/j.1600-0536.2001.450601.x","article-title":"Guidelines for performing skin tests with drugs in the investigation of cutaneous adverse drug reactions","volume":"45","author":"Barbaud","year":"2001","journal-title":"Contact Dermat."}],"container-title":["Toxicology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214750025001283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214750025001283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:46:28Z","timestamp":1750207588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214750025001283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":22,"alternative-id":["S2214750025001283"],"URL":"https:\/\/doi.org\/10.1016\/j.toxrep.2025.102010","relation":{},"ISSN":["2214-7500"],"issn-type":[{"type":"print","value":"2214-7500"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fixed drug eruption induced by Etoricoxib in Thailand: A case report","name":"articletitle","label":"Article Title"},{"value":"Toxicology Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.toxrep.2025.102010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102010"}}